Disease duration as an indicator of the efficacy of liraglutide in patients with type 2 diabetes mellitus
Publication year
2018Source
Journal of Diabetes Investigation, 9, 4, (2018), pp. 979-980ISSN
Publication type
Article / Letter to editor

Display more detailsDisplay less details
Organization
Internal Medicine
Rheumatology
Journal title
Journal of Diabetes Investigation
Volume
vol. 9
Issue
iss. 4
Page start
p. 979
Page end
p. 980
Subject
Radboudumc 5: Inflammatory diseases RIHS: Radboud Institute for Health SciencesAbstract
Comment on the article of Usui et al. Retrospective cohort study of obese patients with type 2 diabetes mellitus (n = 69) demonstrates that the glucose-lowering effect of liraglutide as add on therapy to insulin relies on the remaining beta-cell function in type 2 diabetes. Shorter disease duration implies a more favourable prognosis for response on instantaneous substitution of insulin with liraglutide (HR 2.39 (95% CI: 1.20-4.76).
This item appears in the following Collection(s)
- Academic publications [227244]
- Electronic publications [108520]
- Faculty of Medical Sciences [86731]
- Open Access publications [77772]
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.